"I am who I am"-
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The massive shorting could be a function of the many outstanding shares available ????
However my post has to do with not you at all but some self aggrandizing
Multi- millionaire Alaskan
Who seems to think that the pebble will kill the sockeye
And he refuses to accept the science presented by northern dynasty
It’s an old school approach to get the Alaskans to be against the mine
I am for economic progress and have always been so
If it’s safe to build the mine
Then do it
Our country needs to help itself
Thanks for your reply
A clear understand of the pebble makes it easier to support and keep invested in
So
When mark Hamilton writes that the site for the mine produces 1/10 of 1% of the sockeye
Is he deliberately leaving out the yellow dotted areas
This was a well written article
I’m glad to see lilac is still in this stock
Always. Good postings from a Long Island ny lady
And I thought all the money in treating horse ulcers would have convinced people to buy more shares
Massive dumping
Can’t even break and hold 5 bucks
Best way to handle a big deal like this would be zipped lips 100%
It’s gonna happen
Whether it’s a total takeover or a partnership
Get ready
I’ve never been so sure
Not sure why you think the management team is bad ?
Agreed
Steady stream of news will move this up
Even if it’s about horse ulcers
Anything is good iMO
As soon as investors believe this company has something worth investing in
The share price will rise
Until then news about horse ulcer is more a farce than anything else
What a ridiculous pr
Im waiting and my original buy in was 4.70
If that is not fake news
Hmmm.....
Big money market too
Oh crap this is funny
Updated
It will be sooner
Well what about today ?
I’m
Getting ready to go swimming
While reading through comments on Thea recent SA article
I was reminded that Mr Thiessen reiterated that he seeks a partnership in Q4
This comment was made in late November
All systems go
One day
Will come and this stock will out of nowhere
Go up and go up a lot
For me
Yes before December 31 would be nice
I like the action
However the writing is on the wall
It will happen
Best of luck
Plus it’s a safe mine that will protect the fish
Create jobs
Tax revenues for the state and do a lot more
You know there is never a project that an environmentalist likes when it comes to economic progress and using the land
And this one in a remote part of Alaska is just a good deal
I figured
Thats not what I’m saying at all
What I’m saying is that he promotes stocks but shorts them and has people who follow his short advice and jump on board
It’s devious
Just a dishonest person as I see it
However good
Earnings
News etc will drive the share price up
It always does
Yo ruff
That Clay dude was exposed on another board as a short seller who
Promotes stocks but shorts them secretly
Apparently many know his game
Hope so
Weeeeeee...
Is that a correction ????
Definitely so
You are so smart
Yeah
But it will probably correct tomorrow
and go to 4.40
Ugh
Good
Luck 2U
I own another biotech( crazy me) and all of a sudden after miserable price performance fora long time it’s going up today
Avxl will do the same at some point In Time
All depends on what you are looking for
Granted Thiessen said the share price could go back above 20
In 2019
All depends what you want here
This investment is a no brainer
Upward move In price today
Relaxing for sure
I hate to think what will happen to this. Stock if the market corrects 5-10%
Without the three trials that were said to be gong this year
The traders are having a field day
Just chipping away and today looks terrible
Good idea
Wow my credibility is on the line
I said this week for news
And ...
With the fantastic strength in the markets
Now would be a great time to go public with an announcement
Go NAK
Before December 31 ???
Where is my news ???? ugh
Warped mentality
I’m out of the country or I would do it
Looks like he is trying his best
Good article for a local newspaper
I’ve noticed some real b/s postings here
Pay attention
Good luck
It’s just a hunch
Do read anything more into it please
Remember,
This could be the week
First week of December
Adamis Pharmaceuticals Announces Presentation of Results of a Human Factors Study Conducted With Its Newly Approved Epinephri...
Source: GlobeNewswire Inc.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today the acceptance of a presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic Reactions (Type I) Including Anaphylaxis”. The presentation will be for the American Academy of Allergy, Asthma, and Immunology (AAAAI) joint congress with the World Allergy Organization and will be held in Orlando, Florida on March 3, 2018. This premier annual educational event draws thousands of healthcare professionals including allergists, immunologists and other medical specialists.
Dr. Dennis J. Carlo, President/CEO of Adamis stated, “Symjepi was studied in trained and untrained adults, adolescents and caregivers. The results definitively showed Symjepi to be an easy to use, small and intuitive device.” Dr. Ronald Moss, Chief Medical Officer at Adamis and a Fellow of AAAAI stated, “For a layperson, treatment of anaphylaxis with a simple non-threatening device is critical to successful use.” The presentation will focus on the successful human factors study utilizing Symjepi.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. The company’s first product, Symjepi (epinephrine) Injection 0.3mg, was approved in June 2017 for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’ product pipeline includes HFA metered dose inhaler and dry powder inhaler products for the treatment of bronchospasm and asthma.
The Company’s U.S. Compounding, Inc. (USC) subsidiary, which is registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act and the U.S. Drug Quality and Security Act, compounds sterile prescription drugs, and certain nonsterile drugs, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.
Adamis Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations, including, but not limited to the following statements: the status of anticipated presentations by the company at upcoming conferences; the company's beliefs concerning the ability of its products and product candidates to compete successfully in the market; the company’s beliefs concerning the results of studies relating to Symjepi and user perceptions of Symjepi; and the company's beliefs concerning the safety and effectiveness of its products and product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis' actual results to be materially different from those contemplated by these forward-looking statements. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Any forward-looking statement in this press release speaks only as of the date on which it is made. Except to the extent required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.
Contacts:
Mark Flather
Senior Director, Investor Relations
& Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com
Primary Logo
Don’t you know how to post info here ?
No problem I’ll find it later
Can you post here ?